PRISM study highlights possibility of reducing dose of immunotherapy
The CheckMate-214 clinical trial was the first study to show [...]
Injectable form of nivolumab
An injectable form of nivolumab has been successful in clinical [...]
Corticosteroids during treatment with nivolumab may not affect survival in kidney cancer
A recent study published in the journal JAMA Oncology has [...]
Nivolumab plus cabozantinib for advanced non-clear cell kidney cancer
Updated results and further follow up from the CaboNivo study [...]
Promising new anti-cancer treatment for advanced kidney cancer
The results of a study with a new anti-cancer medication [...]
Triple combination for previously untreated advanced non-clear cell kidney cancer
The COSMIC-313 study previously showed improved survival when combining cabozantinib [...]
Triple combination improves survival in patients with advanced kidney cancer
Results from the phase 3 COSMIC-313 trial showed that adding [...]
Brain metastases from kidney cancer treated with first-line therapies
A recent study looked at the outcomes of patients with [...]
Adjuvant nivolumab plus ipilimumab for localised kidney cancer
In this randomised phase 3 trial, the effectiveness and safety [...]
How time of day of immunotherapy infusion affects kidney cancer outcomes
Recent studies have suggested that the time of day when [...]
